[ANCA associated glomerulonephritis: Pathogenesis, pathophysiology, and therapy].
Arimura
Yoshihiro
Y
First Department of Internal Medicine, Kyorin University School of Medicine.
D000483:Alleles; D000818:Animals; D019268:Antibodies, Antineutrophil Cytoplasmic; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D013956:Antithyroid Agents / Q000009:adverse effects; D005921:Glomerulonephritis / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D006680:HLA Antigens / Q000235:genetics; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D000069285:Infliximab; D008070:Lipopolysaccharides; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D018375:Neutrophil Activation / Q000235:genetics; D011441:Propylthiouracil / Q000009:adverse effects; D012822:Silicon Dioxide / Q000009:adverse effects; D013211:Staphylococcus aureus / Q000472:pathogenicity; D014657:Vasculitis / Q000150:complications / Q000276:immunology; D000515:alpha 1-Antitrypsin / Q000235:genetics; D005719:gamma-Globulins / Q000627:therapeutic use
D019268:Antibodies, Antineutrophil Cytoplasmic; D000911:Antibodies, Monoclonal; D013956:Antithyroid Agents; D006680:HLA Antigens; D007166:Immunosuppressive Agents; D008070:Lipopolysaccharides; D000515:alpha 1-Antitrypsin; D005719:gamma-Globulins; D011441:Propylthiouracil; D012822:Silicon Dioxide; D000069285:Infliximab; D009173:Mycophenolic Acid